Please login to the form below
Case study: Opportunity Assessment for a Rare Disease Product in Emerging Markets
Using in-depth-interviews to determine how to maximise the commercial opportunities in different emerging markets
We have recently produced a guide to conducting effective
market research in rare diseases, based on our experience in a broad number of
disease areas.
Our client had a product indicated for a rare Haematology disease. Whilst this product was successfully launched in over 40 countries globally, it had a limited presence in many emerging markets. Our client needed to conduct market research in order to determine how to maximise the commercial opportunities in each of these different emerging markets.
Read the full case study here:
http://www.researchpartnership.com/news/2015/11/case-study-opportunity-assessment-for-a-rare-disease...
Our client had a product indicated for a rare Haematology disease. Whilst this product was successfully launched in over 40 countries globally, it had a limited presence in many emerging markets. Our client needed to conduct market research in order to determine how to maximise the commercial opportunities in each of these different emerging markets.
Read the full case study here:
http://www.researchpartnership.com/news/2015/11/case-study-opportunity-assessment-for-a-rare-disease...
Company Details
Research Partnership
+44 (0)20 8069 5000
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Interactive infographic
- Living With: The journey from the patient’s perspective
Research Partnership
- Article: Spotlight on Mexico
- Healthcare under AMLO – One year on
Research Partnership
- News: Mandira Kar joins London Headquarters as Qualitative Research Director
Research Partnership
- Conference Live
- Global medical conferences and events calendar 2020
Research Partnership
- Announcing a change of leadership at the US Philadelphia office
Research Partnership
- Article: Market access in Brazil
- All eyes on Spinraza
Research Partnership
